Share chart Madrigal Pharmaceuticals, Inc.
Extended chart
Simple chart
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., биофармацевтическая компания на клинической стадии, специализируется на разработке и коммерциализации терапевтических кандидатов для лечения сердечно-сосудистых, метаболических заболеваний и заболеваний печени. Его ведущим кандидатом в продукт является MGL-3196, избирательный агонист рецептора тироидных гормонов, направленный на печень, который проходит III фазу клинических испытаний для лечения неалкогольного стеатогепатита. Компания заключила соглашение с Hoffmann-La Roche об исследованиях, разработках и коммерциализации. more detailsMain settings
| IPO date | 2007-02-06 |
|---|---|
| ISIN | US5588681057 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | link |
| Цена ао | 267.56 |
| Change price per day: | 0% (267.56) |
|---|---|
| Change price per week: | -7.97% (290.72) |
| Change price per month: | -16.37% (319.93) |
| Change price per 3 month: | -16.94% (322.14) |
| Change price per half year: | -20.54% (336.74) |
| Change price per year: | +16.54% (229.58) |
| Change price per 3 year: | +265.27% (73.25) |
| Change price per 5 year: | +130.62% (116.02) |
| Change price per 10 year: | +11 533.04% (2.3) |
| Change price per year to date: | -14.24% (312) |
Grade
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
Insider trading
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Price (T.Rowe) Associates Inc | 803 | 3.77 |
| FMR, LLC | 714 | 3.35 |
| State Street Corporation | 625 | 2.93 |
| Perceptive Advisors LLC | 430 | 2.02 |
| Janus Henderson Group PLC | 3 | 12.21 |
| Baker Brothers Advisors, LLC | 2 | 9.24 |
| Avoro Capital Advisors LLC | 2 | 9.12 |
| Paulson & Company, Inc. | 2 | 8.33 |
| Vanguard Group Inc | 2 | 7.83 |
| Blackrock Inc. | 1 | 5.68 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Future Tech ETF | 0.49184 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.49184 | 618.5 | 0.8416 |
| iShares Morningstar Small-Cap Growth ETF | 0.15948 | 595.05 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.08005 | 391.25 | 1.60498 |
| 0.3 | 507.79 | 1 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 939.83k | 1952 (73 years) |
| Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | N/A | |
| Mr. William J. Sibold | CEO, President & Director | N/A | 1966 (59 years) |
| Mr. Ronald Filippo | Chief Information Officer | N/A | |
| Ms. Mardi C. Dier | CFO & Senior VP | N/A | 1964 (61 year) |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | N/A | |
| Mr. Clint Wallace | Chief Human Resources Officer | N/A | |
| Ms. Carole Huntsman | Chief Commercial Officer | 1965 (60 years) | |
| Ms. Shannon Kelley | Chief Compliance Office & General Counsel | ||
| Mr. Thomas W. Hare | Senior Vice President of Clinical Management |
About company
Address: United States, West Conshohocken, Four Tower Bridge - Open in google maps, Open in yandex maps
Website: https://www.madrigalpharma.com
Website: https://www.madrigalpharma.com
